Medigene AG
MediGene AG english
MediGene discontinues the development of Etomoxir
Ad-hoc-announcement processed and transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
MediGene discontinues the development of Etomoxir for the treatment of
congestive heart failure
Martinsried / San Diego, June 14, 2002. The German-American biopharmaceutical
company MediGene announced today that the examination of data obtained from the
Phase II clinical trial of its product candidate Etomoxir indicates that
Etomoxir did not have the expected efficacy in the treatment of congestive
heart failure (CHF). MediGene therefore discontinues the development of
Etomoxir. Etomoxir is one of seven product candidates being developed by
MediGene for the treatment of indications in cardiology and oncology.
For further information please contact:
MediGene AG Email: investort@medigene.com
Fax: ++49 – 89 -85 65-2920
Julia Hofmann/
Julia von Hummel, Public Relations Tel: ++49 – 89 -85 65 -3324/-2916
Angelica Heinz, Investor Relations Tel: ++49 – 89 -85 65 -2946
end of ad-hoc-announcement (c)DGAP 14.06.2002
——————————————————————————–
WKN: 502090; ISIN: DE0005020903; Index: NEMAX-50
Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf,
Hamburg, Hannover, München und Stuttgart
141218 Jun 02
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden